New Clinical Trial: Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm (NCT05546866)
WHY IT MATTERS
If you have non-small cell lung cancer with an uncommon EGFR mutation and have had surgery, this trial is testing a targeted drug that may reduce your risk of cancer returning — but the trial is no longer accepting new patients.
Researchers are testing a drug called osimertinib to see if it can help people with a specific type of lung cancer after surgery. This cancer has uncommon changes in a gene called EGFR. The study includes 51 patients and is checking whether the drug is safe and effective when given after the cancer is surgically removed.
NCT ID: NCT05546866 Status: ACTIVE_NOT_RECRUITING Conditions: Non-small Cell Lung Cancer Phase: PHASE2 Enrollment: 51 Sponsor: AstraZeneca Summary: This is an open-label, multi-centre, single-arm study assessing the efficacy and safety of osimertinib as adjuvant treatment in stage IB-IIIB (8th AJCC) NSCLC with uncommon EGFRm after receiving complete surgical resection with or without adjuvant chemotherapy.